Section Arrow
LQDA.NASDAQ
- Liquidia Corp
Quotes are at least 15-min delayed:2025/07/17 16:45 EDT
After Hours
Last
 14.25
-0.35 (-2.40%)
Bid
14.25
Ask
14.67
High 14.61 
Low 14.25 
Volume 37489 
Regular Hours
Last
 14.6
+0.41 (+2.89%)
Day High 
14.64 
Prev. Close
14.19 
1-M High
14.99 
Volume 
1.56M 
Bid
14.25
Ask
14.67
Day Low
14.04 
Open
14.1 
1-M Low
11.85 
Market Cap 
1.21B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 13.44 
20-SMA 13.29 
50-SMA 15.01 
52-W High 19.41 
52-W Low 8.26 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.71/-0.66
Enterprise Value
1.32B
Balance Sheet
Book Value Per Share
0.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.00M
Operating Revenue Per Share
0.21
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.1.05+0.15+16.67%0.84PE
After Hours 1.1 +0.05 +4.76%
ABPAbpro Holdings Inc0.1962-0.022-10.08%-- 
After Hours 0.196 -0.0002 -0.10%
NCNANuCana plc0.0468-0.0034-6.77%-- 
After Hours 0.0469 +0.0001 +0.21%
ATNF180 Life Sciences Corp1.83+0.9497+107.88%0.11PE
After Hours 1.7298 -0.1002 -5.48%
MRKRMarker Therapeutics1.92+0.32+20.00%-- 
After Hours 1.92 0 0.00%
Quotes are at least 15-min delayed:2025/07/17 16:45 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.